Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Understanding the biology of the disease to guide treatment choices

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.01.14
Views: 2464

Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Ireland

Prostate cancer is a heterogeneous disease with co-existence of AR-positive and AR-negative tumour cells in a given patient. Tumour progression is the result of 2 main theories: 

(1) adaptation of AR-positive tumour cells to a low testosterone environment by ligand-dependent and ligand-independent activation of AR signaling

(2) clonal proliferation of AR negative cells which bypass the AR receptor by various mechanisms  (inhibition of apoptosis, stimulation of EMT, cancer stem cells…).

The mode of action of current therapeutic strategies for mCRPC (taxanes, AR targeted agents) will be described.


Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation